About Cardurion Pharmaceuticals
Cardurion Pharmaceuticals is a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of cardiovascular diseases. Founded by physician-scientists with expertise in cardiovascular signaling pathways, the company is advancing two groundbreaking clinical programs: a first-in-class PDE9 inhibitor for heart failure and the first clinical-stage CaMKII inhibitor for rare and common cardiovascular diseases. Its customers are patients with chronic heart failure and related cardiovascular conditions.
Company details
Funding
Total raised
$560M
Last stage
Series B
Investors
Founders
Michael E. Mendelsohn
Physician-scientist with world-class expertise in cardiovascular signaling pathways. Founded Cardurion in 2017.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.